GALD.SW Galderma Group N

Healthcare Drug Manufacturers - Specialty & Generic SIX Swiss Exchange
192.85 CHF
Close of Oct 31, 2026
136.00 193.90
Market cap
CHF 45.0B
P/E
66.5x
P/B
6.50x
ROE
21.1%
Dividend yield
0.18%
Fundamental score
2.1/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is GALD.SW undervalued?

Graham number

The Graham number of Galderma Group N cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Galderma Group N fundamental analysis

9 of 22 checks passed

ROE 2/2

High return on equity (21.1%), above 20%.

ROA 1/1

Return on assets (12.8%) is above the industry median (3.7%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (153.3%) is above the industry median (24.7%).

Revenue Growth 2/2

Revenue grew 10.5% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (32.8%), 40% or less.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

EBIT is 7.4x against interest expense, well covered.

PE vs Market 0/1

PE (66.5x) is above the market median (21.2x).

PE vs Industry 0/1

PE (66.5x) is above the industry median (19.0x).

PBV 0/1

Price to book (6.5x) is above the industry median (2.6x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 431.9, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

Dividend yield (0.1%) is in the bottom 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 1/1

Payout ratio is 6.4%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Galderma Group N stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Galderma Group N

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac…

Full company profile